Chris Ellis
Geschäftsführer bei Vaccitech (UK) Ltd.
Vermögen: 182 $ am 30.04.2024
Profil
Chris Ellis is currently the Chief Operating Officer at Vaccitech (UK) Ltd.
Prior to this, he worked as a Project Leader at Akamis Bio Ltd.
from 2013 to 2016.
He also held the position of Head-Clinical Operations at Barinthus Biotherapeutics Plc from 2016 to 2023.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
03.01.2023 | 75 ( 0,00% ) | 182 $ | 30.04.2024 |
Aktive Positionen von Chris Ellis
Unternehmen | Position | Beginn |
---|---|---|
Vaccitech (UK) Ltd.
Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | Geschäftsführer | 01.08.2016 |
Ehemalige bekannte Positionen von Chris Ellis
Unternehmen | Position | Ende |
---|---|---|
BARINTHUS BIOTHERAPEUTICS PLC | Geschäftsführer | 31.10.2023 |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Corporate Officer/Principal | 01.08.2016 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BARINTHUS BIOTHERAPEUTICS PLC | Health Technology |
Private Unternehmen | 2 |
---|---|
Vaccitech (UK) Ltd.
Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | Commercial Services |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |